Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04590885
Other study ID # Pro00103232
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 20, 2020
Est. completion date December 31, 2024

Study information

Verified date August 2023
Source Duke University
Contact Laura Porter, PhD
Phone 919-416-3436
Email Laura.Porter@duke.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of the proposed study is to evaluate the Couple Communication Skills Training (CCST) intervention in 250 patients with advanced cancer and their spouses/intimate partners. Couples will be randomized 1:1 to receive either the CCST or to an attention control condition (Healthy Living Information; HLI). We will evaluate CCST effects on a range of patient and partner relationship and psychological outcomes.


Description:

For patients and their intimate partners, advanced cancer poses significant challenges that can negatively impact both individuals and the couple's collective well-being. Couples' ability to communicate openly and effectively with each other about cancer-related concerns can improve their psychological adjustment and quality of their relationship. Open and effective communication may also lead to better symptom management and goal-concordant care. However, many couples report difficulties communicating about cancer, even in the context of overall satisfying relationships. This can have a number of deleterious consequences, including deficits in emotional support, decreases in intimacy and relationship quality, and increased psychological distress. Thus, interventions designed to facilitate effective communication between cancer patients and their partners are likely to have beneficial effects on both individual and relationship functioning. Prior research, including studies conducted by our team, has found that couple-based interventions that target communication lead to positive outcomes for cancer patients and their partners. However, most prior studies have been limited by reliance on an in-person treatment delivery format which keeps many couples from participating. In addition, prior studies have not targeted interventions to couples who are most likely to benefit. There is increasing evidence that psychosocial interventions for cancer, including couple-based interventions, should be targeted to those at risk of poor outcomes. Our prior research indicates that couples who report communication difficulties (e.g., high levels of holding back from discussing cancer-related concerns) have increased psychological distress and poorer relationship functioning and are most likely to benefit from a couple communication intervention specifically designed to addressed their communication problems. The specific aims of this study are (1)To determine whether CCST significantly improves patients' and partners' individual psychological adjustment (i.e., psychological distress, life completion) and patient health and health care outcomes (physical well-being, symptom distress, advance care planning discussions and completion of advance directives, hospitalizations, and emergency department visits) compared to an education condition. (2) To determine whether, for couples receiving the CCST intervention, improvements in psychological adjustment, relationship functioning, and patient health are mediated by improvements in their communication, including objective measures of communication quality and communal coping (e.g., "we-talk") derived from couple conversations and self-reported protective buffering. (3) To examine differences in response to the CCST intervention for patients versus partners, for male versus female participants, and for patients with different cancer diagnoses (breast, lung, GI, GU). (4) To conduct an implementation-related process evaluation of the intervention.


Recruitment information / eligibility

Status Recruiting
Enrollment 460
Est. completion date December 31, 2024
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Married or in a committed intimate relationship 2. Diagnosis of one the following advanced cancers: Stage IIIB or IV non-small cell lung cancer or extensive stage small cell lung cancer, Stage III pancreatic cancer or Stage IV GI cancer, Stage IV GU cancer, Stage IV breast cancer and GYN cancer Stage III-IV ovarian, IV uterine, IV cervical. 3. Both members of the couple must speak and read English. 4. Patient and/or partner scores >=1.0 on the Holding Back screen. Exclusion Criteria: 1. Patient lacks capacity for interview (documented diagnosis of active psychosis or dementia) or is unable to provide informed consent as assessed by research staff. 2. Patient has a life expectancy < 6 months as estimated by his/her treating oncologist. 3. Patient or partner is physically impaired in such a way that precludes the use of a computer or videoconferencing. 4. Patient or partner is too sick to participate, as judged by the oncologist or research staff.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Couple Communication Skills Training
Participants attend six 60-minute sessions consisting of education and skills training to enhance cancer-related communication.
Healthy Lifestyle Information
Participants attend attend six 60-minute sessions consisting of information and support across a range of cancer-related topics.

Locations

Country Name City State
United States Duke University Medical Center Durham North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Duke University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in patient relationship functioning Change in patient relationship satisfaction measured by the Couples Satisfaction Inventory (higher scores indicate higher satisfaction) Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up
Primary Changes in partner relationship functioning Change in partner relationship satisfaction measured by the Couples Satisfaction Inventory (higher scores indicate higher satisfaction) Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up
Primary Changes in patient relationship functioning Change in patient intimacy as measured by the Miller Social Intimacy Scale (higher scores indicate higher intimacy) Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up
Primary Changes in partner relationship functioning Change in partner intimacy as measured by the Miller Social Intimacy Scale (higher scores indicate higher intimacy) Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up
Secondary Changes in patient psychological functioning Change in patient psychological distress measured by the Hospital Anxiety and Depression Scale (higher scores indicate higher distress) Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up
Secondary Changes in partner psychological functioning Change in partner psychological distress measured by the Hospital Anxiety and Depression Scale (higher scores indicate higher distress) Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up
Secondary Changes in patient psychological functioning Change in patient mood as measured by the Positive and Negative Mood Scale (higher scores on the positive and negative mood subscales indicate higher negative and positive mood, respectively) Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up
Secondary Changes in partner psychological functioning Change in partner mood as measured by the Positive and Negative Mood Scale (higher scores on the positive and negative mood subscales indicate higher negative and positive mood, respectively) Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up
Secondary Changes in patient psychological functioning Change in patient life completion measured by the Life Completion scale of the QUAL-E (higher scores indicate higher completion) Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up
Secondary Changes in partner psychological functioning Change in partner life completion measured by the Life Completion scale of the QUAL-E Family (higher scores indicate higher completion) Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up
Secondary Changes in patient psychological functioning Change in patient physical well being as measured by the Physical Well Being subscale of the Functional Assessment of Cancer Therapy scale (higher scores indicate higher physical well being) Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up
Secondary Changes in patient and partner psychological functioning Change in symptom distress as measured by the Condensed Memorial Symptom Assessment Scale (higher scores indicate higher symptom distress) Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up
Secondary Changes in patient psychological functioning Change in patient advance care planning discussions (presence or absence, via patient self-report) Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up
Secondary Changes in patient psychological functioning Change in patient completion of advanced directives (presence or absence, via patient self-report) Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up
Secondary Changes in patient psychological functioning Change in patient hospitalizations (number of hospitalizations per patient self-report, validated by medical record review) Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up
Secondary Changes in patient psychological functioning Change in patient emergency department visits (number of emergency department visits per patient self-report, validated by medical record review) Baseline, end of intervention (up to 8 months), 3 month post intervention follow-up
See also
  Status Clinical Trial Phase
Completed NCT03181854 - Randomized Controlled Trial of Integrated Early Palliative Care N/A
Completed NCT01197170 - Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance Phase 1
Recruiting NCT05045040 - Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions N/A
Active, not recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03994601 - An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers Phase 1/Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Completed NCT01393990 - A Study of LY2228820 in Participants With Advanced Cancer Phase 1
Completed NCT02857270 - A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer Phase 1
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Active, not recruiting NCT04121676 - Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer Phase 1
Active, not recruiting NCT03177291 - Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC Phase 1
Completed NCT03980041 - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Phase 2
Active, not recruiting NCT03674567 - Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab Phase 1/Phase 2
Recruiting NCT04823377 - Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer. N/A
Completed NCT02778126 - A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer Phase 1
Completed NCT02529553 - A Study of LY3076226 in Participants With Advanced or Metastatic Cancer Phase 1
Completed NCT02507544 - A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer Phase 1
Completed NCT02245204 - Phase I Studies of Chlorogenic Acid for Injection for Tolerance and Pharmacokinetic of Advanced Cancers Phase 1
Terminated NCT01929941 - An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies Phase 1
Completed NCT01583777 - Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer Phase 1